

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

Grouzmann, *et al.*

Appl. No.: 09/897,433

Filed: July 3, 2001

For: **Treatment of Substance P-Related Disorders**



Art Unit: to be assigned

Examiner: to be assigned

Atty. Dkt. 81985/279329

Information Disclosure Statement

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herewith is a listing of documents known to Applicants and/or their attorney in compliance with the requirements of 37 C.F.R. § 1.56. Copies of the listed documents are also enclosed.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned attorney submits the following concise explanation of the relevance of the non-English language document cited on the accompanying form:

Reference AJ1, PCT published application WO 93/09116, describes quinuclidine derivatives that act as substance P antagonists. The derivatives can be used to treat pain and disorders of the respiratory, CNS, cardiovascular and digestive systems. An English language abstract corresponding to this document is cited on the accompanying list of references as document AM7.

Reference AJ2, European patent document EP 0 514 274, describes perhydro-isoindole derivatives used as intermediates for substance P antagonists. An English language abstract corresponding to this document is cited on the accompanying list of references as

document AN7. In addition, a corresponding United States patent, U.S. 5,508,433, is enclosed herewith and is cited on the accompanying list of references as document AE1.

Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the present application. This statement should not be construed as a representation that more material information does not exist or that an exhaustive search of the relevant art has been made.

Consideration of the cited documents and making the same of record in the prosecution of the above-captioned application are respectfully requested. It is believed that all fees due for consideration of this Information Disclosure Statement have been provided for herewith. Any additional fees which may be due may be charged to our Deposit Account No. 03-3975.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By: Michael A. Sanzo
Michael A. Sanzo
Reg. No. 36,912
Attorney for Applicants

Date: October 22, 2001

1600 Tysons Boulevard
McLean, VA 22102
(703) 905-2173